Luma Ghalib

Dr. Luma Ghalib

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2018 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
PNPratima Nayak
Pratima Nayak
AMAlaa S Montaser
Alaa S Montaser
Jie HuJie Hu
Jie Hu
DPDaniel M Prevedello
Daniel M Prevedello
LKLawrence S Kirschner
Lawrence S Kirschner
LGLuma Ghalib
Luma Ghalib
Context The development of diabetes insipidus (DI) following transsphenoidal resection of pituitary adenomas has been associated with higher postsurgical morbidity and longer hospitalizations. Identifying these patients promptly and efficiently can lead to improved healthcare outcomes. Objective We evaluated our institution’s incidence of DI following pituitary adenoma resection and assessed for preoperative risk factors that were associated with postoperative DI. Design A retrospective review of 271 patients who underwent endoscopic endonasal resection of a pituitary adenoma between July 2010 and December 2016 by a single neurosurgical provider was completed. Setting All cases were from a single center, academic institution. Patients Patients with a pituitary adenoma diagnosis confirmed on histology were included in the study. Those with previous surgery by a different provider were excluded. Results The incidence of DI at our institution was 16.6% (45 of 271 patients) with only 4% (11 patients) having permanent DI. The presence of visual abnormalities (CI 1.29-4.75), suprasellar extension (CI 1.36-6.88), and maximal tumor diameter (1.02-1.08) were significantly associated with an increased incidence of postoperative DI (p < 0.05). Hyperprolactinemia, tumor functionality and CSF exposure were not associated with higher rates of postoperative DI (p > 0.05). Conclusion Pituitary adenoma patients presenting with visual abnormalities, suprasellar extension or large tumors are at higher risk of developing DI postoperatively. These patients warrant closer postoperative monitoring as well as adequate preoperative counseling to decrease their postsurgical morbidity.

30 November 2023 in Archives of Medical Research
Verified
Journal Article
Closed access
IZIngrid Marijke Zandbergen
Ingrid Marijke Zandbergen
KHKristin Michelle Huntoon
Kristin Michelle Huntoon
TWTimothy G White
Timothy G White
LBLeontine Erica Henriëtte Bakker
Leontine Erica Henriëtte Bakker
MVMarco Johanna Theodorus Verstegen
Marco Johanna Theodorus Verstegen
DPDaniel M. Prevedello
Daniel M. Prevedello


20 November 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
CBChandrima Biswas
Chandrima Biswas
GMGuilherme Mansur
Guilherme Mansur
KWKyle C. Wu
Kyle C. Wu
DPDaniel M. Prevedello
Daniel M. Prevedello
LGLuma Ghalib
Luma Ghalib
Introduction: Craniopharyngiomas (CPs) are benign and rare tumors found in adults. Their location close to vital neurovascular structures makes traditional treatment modalities (surgery and radiation) challenging and potentially fraught with morbidity. The 2021 WHO classification has divided what was previously considered two subtypes of craniopharyngioma into separate entities. Identification of specific molecular driver mutations in each type- BRAF V600E in papillary craniopharyngiomas (PCP) and CTNNB1 in adamantinomatous craniopharyngiomas (ACP) has resulted in a paradigm shift in the management of adult CPs.Methods: In this study, we describe our experience in treating PCPs with targeted therapy and highlight nuances in management accounting for current evidence. This review also explores the current scope and application of precision oncology in adult CPs including the experience with ongoing trials and prospects for future research.Results: The high prevalence of targetable mutation in cases of PCP and the efficacy of BRAF inhibitors alone or in combination with MEK inhibitors has improved the disease control in these patients. In the current scenario, while surgery is warranted to obtain histopathological diagnosis, radical resection and its associated risks can be avoided. In case of ACPs, dysregulation of multiple pathways has been implicated. This has prompted the use of a variety of targeted therapies with inconsistent outcomes. The results of ongoing and future trials may define its role in management.Conclusion: Precision oncology is a promising addition to the treatment armamentarium of adult CPs.

1 May 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
ARAakash Rajwani
Aakash Rajwani
LGLuma Ghalib
Luma Ghalib
Pituitary hyperplasia is defined as an absolute increase in the number of one or more adenohypophyseal cell subtypes, manifesting radiologically as pituitary enlargement beyond what is considered normal. It has been noted in certain physiological conditions like pregnancy however can also be seen in pathological conditions with end organ insufficiency like severe hypothyroidism. 21- year old female with a past medical history of Primary Hypothyroidism secondary to Hashimoto’s thyroiditis presented initially for evaluation of worsening headache and blurry vision. She was diagnosed with hypothyroidism at 10 years of age and had an extensive family history of hypothyroidism. At the time of presentation, she was 11 months post- partum and had been on and off her levothyroxine supplementation, having stopped it completely for a few months after delivery. MRI brain showed an 18 mm homogeneously enhancing intrasellar mass with suprasellar extension. She was referred to Neurosurgery for further evaluation. Workup revealed a TSH >100 (0.27 - 4.2 mIU/L) and FT4 <0.4 (0.8 - 2 ng/dL). In the context of severe untreated hypothyroidism and MRI findings consistent with pituitary hyperplasia with abutment but no mass effect on the optic apparatus, initial plan was to treat the hypothyroidism medically and observe closely. Patient was started on levothyroxine supplementation. Her TSH improved to 3.367 (0.550 - 4.780 uIU/mL) and FT4 to 2.00 (0.89 - 1.76 ng/dL), ηοωεϖερ she continued to have worsening of visual symptoms. Surgery was considered to decompress the optic nerve, but pre-operative MRI showed a significant decrease in size of the pituitary gland with decreased suprasellar bulging and no mass effect on the optic chiasm. Surgery was subsequently cancelled. Prolonged primary hypothyroidism leads to pituitary hyperplasia due to loss of negative feedback from lack of circulating T4 and T3, leading to excessive TRH secretion from the hypothalamus. The high TRH can lead to thyrotroph as well as lactotroph hyperplasia. Subsequently patients can present with headache, vision changes along with signs and symptoms of hypothyroidism and increased prolactin secretion. It is important to differentiate hyperplasia from other sellar lesions like pituitary macroadenoma or hypophysitis. Patients with hypothyroidism, who have pituitary enlargement diagnosed on brain imaging, should be promptly diagnosed and treated with thyroid hormone replacement. With a higher frequency and improved quality of imaging techniques, we are increasingly coming across scenarios of abnormal findings on imaging. Correlation of radiographic imaging results with a thorough history and biochemical testing is essential prior to proceeding with surgical intervention.

23 May 2019 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
PNPratima Nayak
Pratima Nayak
DPDaniel M Prevedello
Daniel M Prevedello
LKLawrence S Kirschner
Lawrence S Kirschner
LGLuma Ghalib
Luma Ghalib
Pratima Nayak, MD, Daniel M Prevedello, MD, Lawrence S Kirschner, MD, PhD, Luma Ghalib, MD; Response to Letter to the Editor: Predictors of Postoperative Diabe